CORDIS
EU research results

CORDIS

English EN
Biomarkers in Atopic Dermatitis and Psoriasis

Biomarkers in Atopic Dermatitis and Psoriasis

Objective

Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.

Coordinator

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Address

Olshausenstrasse 40
24118 Kiel

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 535 000

Participants (31)

Sort alphabetically

Sort by EU Contribution

Expand all

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 1 567 007,25

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 599 032,50

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 410 937,50

UNIVERSITE DU LUXEMBOURG

Luxembourg

EU Contribution

€ 488 936,25

TAMPEREEN KORKEAKOULUSAATIO SR

Finland

EU Contribution

€ 415 801,25

TAMPEREEN YLIOPISTO

Finland

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 376 250

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH

Austria

EU Contribution

€ 466 711,25

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 63 125

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 647 437,50

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 196 062,50

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 274 500

DEN SELVEJENDE INSTITUTION DANSK BORNEASTMA CENTER

Denmark

EU Contribution

€ 544 118,75

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 258 500

TARTU ULIKOOL

Estonia

EU Contribution

€ 193 500

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 81 250

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 175 125

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

Germany

EU Contribution

€ 221 625

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 59 870

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 161 875

INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA

Luxembourg

EU Contribution

€ 460 360

HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v.

Germany

EU Contribution

€ 149 625

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

EU Contribution

€ 203 250

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 556 750

UNIVERSITAT WIEN

Austria

EU Contribution

€ 208 350

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

LEO PHARMA AS

Denmark

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

PFIZER LIMITED

United Kingdom

UCB BIOPHARMA SPRL

Belgium

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 185 000

Project information

Grant agreement ID: 821511

Status

Ongoing project

  • Start date

    1 April 2019

  • End date

    31 March 2024

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 20 884 846,75

  • EU contribution

    € 10 499 999,75

Coordinated by:

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany